ABSTRACT
Antibiotic-induced loss of intestinal hypoxia boosts the growth of C. albicans in mice.
Subject(s)
Candida albicans , Hypoxia , Animals , Mice , Hypoxia/metabolism , Candida albicans/metabolism , Anti-Bacterial Agents/pharmacology , Candidiasis/microbiology , Candidiasis/prevention & control , Candidiasis/metabolism , Intestines/microbiology , HumansABSTRACT
BACKGROUND: Invasive fungal infections (IFI), prevalent in critically ill ICU patients, have gained attention due to post-COVID-19 epidemiological shifts. Notably, COVID-19-associated aspergillosis and candidiasis pose significant risks. WHO recognises key fungal pathogens, emphasising the need for enhanced research and interventions. METHODS: The CHARTER-IFI study retrospectively examines 186,310 individuals admitted to ICUs in Italy from 01/01/2012-01/09/2023, utilising administrative databases covering around 10 million inhabitants. Adult patients were included having at least one ICU discharge diagnosis of IFI at their first IFI-related hospitalisation and having at least 12 months of available data prior to this hospitalisation. RESULTS: A total of 746 IFI patients discharged from ICU (incidence of 4.0 per 1000 ICU-hospitalised patients), were included. Median age was 68 years, 63% were males, and the overall Charlson Comorbidity Index was 2.2. The top three diagnoses were candidiasis (N = 501, 2.7/1000 ICU-hospitalised patients), aspergillosis (N = 71, 0.4/1000), and pneumocystosis (N = 55, 0.3/1000). The evaluation of the comorbidity profile in IFI patients revealed the presence of hypertension (60.5%), use of systemic GC/antibacterials (45.3% during 12 months before and 18.6% during 3 months before hospital admission), cancer (23.1%), diabetes (24.3%) and cardiovascular diseases (23.9%). The mean (±SD) length of hospitalisation in ICU was 19.9 ± 24.1 days (median 11 days), and deaths occurred in 36.1% of IFI patients (within 30 days from discharge). CONCLUSIONS: This retrospective analysis among ICU-hospitalised patients described the burden of IFI in ICU, and its understanding could be crucial to strengthen surveillance, investments in research, and public health interventions as required by WHO.
Subject(s)
COVID-19 , Intensive Care Units , Invasive Fungal Infections , Humans , Male , Intensive Care Units/statistics & numerical data , Female , Retrospective Studies , Aged , Italy/epidemiology , Invasive Fungal Infections/epidemiology , Middle Aged , COVID-19/epidemiology , Aspergillosis/epidemiology , Aged, 80 and over , Comorbidity , Incidence , Candidiasis/epidemiology , Candidiasis/microbiology , Critical Illness , Adult , SARS-CoV-2 , Hospitalization/statistics & numerical data , Risk FactorsSubject(s)
Abscess , Candida albicans , Candidiasis , Stents , Humans , Stents/adverse effects , Candidiasis/microbiology , Candidiasis/diagnosis , Candida albicans/isolation & purification , Abscess/microbiology , Abscess/diagnostic imaging , Male , Kidney Diseases/microbiology , Tomography, X-Ray Computed , Middle AgedABSTRACT
More than two million people worldwide are affected by life-threatening, invasive fungal infections annually. Candida species are the most common cause of nosocomial, invasive fungal infections and are associated with mortality rates above 40%. Despite the increasing incidence of drug-resistance, the development of novel antifungal formulations has been limited. Here we investigate the antifungal mode of action and therapeutic potential of positively charged, synthetic peptide mimics to combat Candida albicans infections. Our data indicates that these synthetic polymers cause endoplasmic reticulum stress and affect protein glycosylation, a mode of action distinct from currently approved antifungal drugs. The most promising polymer composition damaged the mannan layer of the cell wall, with additional membrane-disrupting activity. The synergistic combination of the polymer with caspofungin prevented infection of human epithelial cells in vitro, improved fungal clearance by human macrophages, and significantly increased host survival in a Galleria mellonella model of systemic candidiasis. Additionally, prolonged exposure of C. albicans to the synergistic combination of polymer and caspofungin did not lead to the evolution of tolerant strains in vitro. Together, this work highlights the enormous potential of these synthetic peptide mimics to be used as novel antifungal formulations as well as adjunctive antifungal therapy.
Subject(s)
Antifungal Agents , Candida albicans , Candidiasis , Caspofungin , Drug Synergism , Peptides , Candida albicans/drug effects , Antifungal Agents/pharmacology , Humans , Caspofungin/pharmacology , Animals , Candidiasis/drug therapy , Candidiasis/microbiology , Peptides/pharmacology , Peptides/chemistry , Macrophages/drug effects , Macrophages/microbiology , Endoplasmic Reticulum Stress/drug effects , Cell Wall/drug effects , Microbial Sensitivity Tests , Mannans/pharmacology , Mannans/chemistry , Moths/microbiology , Moths/drug effects , Epithelial Cells/drug effects , Epithelial Cells/microbiology , Polymers/pharmacology , Polymers/chemistryABSTRACT
OBJECTIVES: The investigation of Candida auris outbreaks is needed to provide insights into its population structure and transmission dynamics. We genotypically and phenotypically characterised a C. auris nosocomial outbreak occurred in Consorcio Hospital General Universitario de Valencia (CHGUV), Spain. METHODS: Data and isolates were collected from CHGUV from September 2017 (first case) until September 2021. Thirty-five isolates, including one from an environmental source, were randomly selected for whole genome sequencing (WGS), and the genomes were analysed along with a database with 335 publicly available genomes, assigning them to one of the five major clades. In order to identify polymorphisms associated with drug resistance, we used the fully susceptible GCA_003014415.1 strain as reference sequence. Known mutations in genes ERG11 and FKS1 conferring resistance to fluconazole and echinocandins, respectively, were investigated. Isolates were classified into aggregating or non-aggregating. RESULTS: All isolates belonged to clade III and were from an outbreak with a single origin. They clustered close to three publicly available genomes from a hospital from where the first patient was transferred, being the probable origin. The mutation VF125AL in the ERG11 gene, conferring resistance to fluconazole, was present in all the isolates and one isolate also carried the mutation S639Y in the FKS1 gene. All the isolates had a non-aggregating phenotype (potentially more virulent). CONCLUSIONS: Isolates are genotypically related and phenotypically identical but one with resistance to echinocandins, which seems to indicate that they all belong to an outbreak originated from a single isolate, remaining largely invariable over the years. This result stresses the importance of implementing infection control practices as soon as the first case is detected or when a patient is transferred from a setting with known cases.
Subject(s)
Antifungal Agents , Candida auris , Candidiasis , Cross Infection , Disease Outbreaks , Drug Resistance, Fungal , Genotype , Phenotype , Whole Genome Sequencing , Humans , Spain/epidemiology , Cross Infection/microbiology , Cross Infection/epidemiology , Candidiasis/microbiology , Candidiasis/epidemiology , Antifungal Agents/pharmacology , Candida auris/genetics , Candida auris/drug effects , Drug Resistance, Fungal/genetics , Microbial Sensitivity Tests , Mutation , Male , Fluconazole/pharmacology , Female , Echinocandins/pharmacology , Middle Aged , Candida/genetics , Candida/drug effects , Candida/classification , Candida/isolation & purificationABSTRACT
Candida auris is an emerging pathogenic yeast that has been categorized as a global public health threat and a critical priority among fungal pathogens. Despite this, the immune response against C. auris infection is still not well understood. Hosts fight Candida infections through the immune system that recognizes pathogen-associated molecular patterns such as ß-glucan, mannan, and chitin on the fungal cell wall. In this study, levels of ß-glucan and mannan exposures in C. auris grown under different physiologically relevant stimuli were quantified by flow cytometry-based analysis. Lactate, hypoxia, and sublethal concentration of fluconazole trigger a decrease in surface ß-glucan while low pH triggers an increase in ß-glucan. There is no inverse pattern between exposure levels of ß-glucan and mannan in the cell wall architecture among the three clades. To determine the effect of cell wall remodeling on the immune response, a phagocytosis assay was performed, followed by quantification of released cytokines by ELISA. Lactate-induced decrease in ß-glucan leads to reduced uptake of C. auris by PMA-differentiated THP-1 and RAW 264.7 macrophages. Furthermore, reduced production of CCL3/MIP-1⺠but not TNF-⺠and IL-10 were observed. An in vivo infection analysis using silkworms reveals that a reduction in ß-glucan triggers an increase in the virulence of C. auris. This study demonstrates that ß-glucan alteration occurs in C. auris and serves as an escape mechanism from immune cells leading to increased virulence.
Subject(s)
Candida auris , Cell Wall , Immune Evasion , beta-Glucans , beta-Glucans/metabolism , Animals , Virulence , Mice , Cell Wall/immunology , Cell Wall/chemistry , Cell Wall/metabolism , Humans , Candida auris/pathogenicity , RAW 264.7 Cells , Candidiasis/microbiology , Candidiasis/immunology , Cytokines/metabolism , Phagocytosis , Macrophages/immunology , Macrophages/microbiology , Mannans/pharmacology , Lactic Acid/metabolism , Disease Models, Animal , THP-1 CellsABSTRACT
Introduction. The development of new antifungal drugs has become a global priority, given the increasing cases of fungal diseases together with the rising resistance to available antifungal drugs. In this scenario, drug repositioning has emerged as an alternative for such development, with advantages such as reduced research time and costs.Gap statement. Propafenone is an antiarrhythmic drug whose antifungal activity is poorly described, being a good candidate for further study.Aim. This study aims to evaluate propafenone activity against different species of Candida spp. to evaluate its combination with standard antifungals, as well as its possible action mechanism.Methodology. To this end, we carried out tests against strains of Candida albicans, Candida auris, Candida parapsilosis, Candida tropicalis, Candida glabrata and Candida krusei based on the evaluation of the MIC, minimum fungicidal concentration and tolerance level, along with checkerboard and flow cytometry tests with clinical strains and cell structure analysis by scanning electron microscopy (SEM).Results. The results showed that propafenone has a 50% MIC ranging from 32 to 256 µg ml-1, with fungicidal activity and positive interactions with itraconazole in 83.3% of the strains evaluated. The effects of the treatments observed by SEM were extensive damage to the cell structure, while flow cytometry revealed the apoptotic potential of propafenone against Candida spp.Conclusion. Taken together, these results indicate that propafenone has the potential for repositioning as an antifungal drug.
Subject(s)
Antifungal Agents , Candida , Microbial Sensitivity Tests , Propafenone , Antifungal Agents/pharmacology , Candida/drug effects , Candida/growth & development , Propafenone/pharmacology , Humans , Itraconazole/pharmacology , Drug Synergism , Drug Resistance, Fungal/drug effects , Candidiasis/microbiology , Candidiasis/drug therapy , Drug RepositioningABSTRACT
Multiple host and microbial factors dictate whether Candida albicans can colonize the mammalian gastrointestinal tract. In this issue of Cell Host & Microbe, Savage et al. demonstrate that restoration of intestinal epithelial hypoxia is sufficient to restore Candida albicans colonization resistance, even when other Candida inhibitory effectors remain depleted.
Subject(s)
Candida albicans , Candidiasis , Gastrointestinal Tract , Candida albicans/growth & development , Candida albicans/physiology , Humans , Gastrointestinal Tract/microbiology , Candidiasis/microbiology , Animals , Hypoxia/metabolism , Intestinal Mucosa/microbiology , Intestinal Mucosa/metabolism , Mice , Host-Pathogen Interactions , Gastrointestinal Microbiome/physiologyABSTRACT
BACKGROUND: Candida auris, a multidrug-resistant fungal pathogen, has received considerable attention owing to its recent surge, especially in South America, which coincides with the ongoing global COVID-19 pandemic. Understanding the clinical and microbiological characteristics of outbreaks is crucial for their effective management and control. OBJECTIVE: This retrospective observational study aimed to characterize a C. auris outbreak at a Peruvian referral hospital between January 2021 and July 2023. METHODS: Data were collected from hospitalized patients with positive C. auris culture results. Microbiological data and antifungal susceptibility test results were analysed. Additionally, infection prevention and control measures have been described. Statistical analysis was used to compare the characteristics between the infected and colonized patients. RESULTS: Thirty-three patients were identified, mostly male (66.7%), with a median age of 53 years. Among them, 18 (54.5%) were colonized, and 15 (45.5%) were infected. Fungemia was the predominant presentation (80%), with notable cases of fungemia in tuberculosis patients with long-stay devices for parenteral anti-tuberculosis therapy. Seventy-five percent of the isolates exhibited fluconazole resistance. Echinocandins were the primary treatment, preventing fungemia recurrence within 30 days. Infected patients had significantly longer hospital stays than colonized patients (100 vs. 45 days; p = .023). Hospital mortality rates were 46.7% and 25% in the infected and fungemia patients, respectively. Simultaneous outbreaks of multidrug-resistant bacteria were documented. CONCLUSIONS: This study underscores the severity of a C. auris outbreak at a referral hospital in Peru, highlighting its significant impact on patient outcomes and healthcare resources. The high prevalence of fluconazole-resistant isolates, leading to prolonged hospital stay and high mortality rates, particularly in cases of fungemia, underscores the critical need for effective infection prevention and control strategies.
Subject(s)
Antifungal Agents , Candida auris , Candidiasis , Disease Outbreaks , Humans , Peru/epidemiology , Middle Aged , Male , Female , Retrospective Studies , Adult , Candidiasis/epidemiology , Candidiasis/microbiology , Antifungal Agents/therapeutic use , Antifungal Agents/pharmacology , Aged , Candida auris/drug effects , COVID-19/epidemiology , Microbial Sensitivity Tests , Cross Infection/epidemiology , Cross Infection/microbiology , Candida/drug effects , Candida/isolation & purification , Candida/classification , Referral and ConsultationABSTRACT
Candida albicans and Staphylococcus aureus are two commonly associated pathogens that cause nosocomial infections with high morbidity and mortality. Our prior and current work using a murine model of polymicrobial intra-abdominal infection (IAI) demonstrates that synergistic lethality is driven by Candida-induced upregulation of functional S. aureus α-toxin leading to polymicrobial sepsis and organ damage. In order to determine the candidal effector(s) mediating enhanced virulence, an unbiased screen of C. albicans transcription factor mutants was undertaken revealing that zcf13Δ/Δ fails to drive augmented α-toxin or lethal synergism during co-infection. A combination of transcriptional and phenotypic profiling approaches shows that ZCF13 regulates genes involved in pentose metabolism, including RBK1 and HGT7 that contribute to fungal ribose catabolism and uptake, respectively. Subsequent experiments reveal that ribose inhibits the staphylococcal agr quorum sensing system and concomitantly represses toxicity. Unlike wild-type C. albicans, zcf13Δ/Δ did not effectively utilize ribose during co-culture or co-infection leading to exogenous ribose accumulation and agr repression. Forced expression of RBK1 and HGT7 in the zcf13Δ/Δ mutant fully restores pathogenicity during co-infection. Collectively, our results detail the interwoven complexities of cross-kingdom interactions and highlight how intermicrobial metabolism impacts polymicrobial disease pathogenesis with devastating consequences for the host.
Subject(s)
Candida albicans , Candidiasis , Coinfection , Fungal Proteins , Staphylococcal Infections , Staphylococcus aureus , Candida albicans/metabolism , Candida albicans/pathogenicity , Candida albicans/genetics , Animals , Coinfection/microbiology , Staphylococcus aureus/pathogenicity , Staphylococcus aureus/metabolism , Staphylococcus aureus/genetics , Staphylococcal Infections/microbiology , Staphylococcal Infections/metabolism , Candidiasis/microbiology , Mice , Fungal Proteins/metabolism , Fungal Proteins/genetics , Bacterial Proteins/metabolism , Bacterial Proteins/genetics , Intraabdominal Infections/microbiology , Female , Transcription Factors/metabolism , Transcription Factors/genetics , Quorum Sensing/genetics , Virulence , Gene Expression Regulation, Fungal , Disease Models, Animal , Trans-Activators/metabolism , Trans-Activators/geneticsABSTRACT
BackgroundThe COVID-19 pandemic and the emergence of Candida auris have changed the epidemiological landscape of candidaemia worldwide.AimWe compared the epidemiological trends of candidaemia in a Greek tertiary academic hospital before (2009-2018) and during the early COVID-19 (2020-2021) and late COVID-19/early post-pandemic (2022-2023) era.MethodsIncidence rates, species distribution, antifungal susceptibility profile and antifungal consumption were recorded, and one-way ANOVA or Fisher's exact test performed. Species were identified by MALDI-ToF MS, and in vitro susceptibility determined with CLSI M27-Ed4 for C. auris and the EUCAST-E.DEF 7.3.2 for other Candida spp.ResultsIn total, 370 candidaemia episodes were recorded during the COVID-19 pandemic. Infection incidence (2.0 episodes/10,000 hospital bed days before, 3.9 during the early and 5.1 during the late COVID-19 era, p < 0.0001), C. auris (0%, 9% and 33%, p < 0.0001) and fluconazole-resistant C. parapsilosis species complex (SC) (20%, 24% and 33%, p = 0.06) infections increased over time, with the latter not associated with increase in fluconazole/voriconazole consumption. A significant increase over time was observed in fluconazole-resistant isolates regardless of species (8%, 17% and 41%, p < 0.0001). Resistance to amphotericin B or echinocandins was not recorded, with the exception of a single pan-echinocandin-resistant C. auris strain.ConclusionCandidaemia incidence nearly tripled during the COVID-19 era, with C. auris among the major causative agents and increasing fluconazole resistance in C. parapsilosis SC. Almost half of Candida isolates were fluconazole-resistant, underscoring the need for increased awareness and strict implementation of infection control measures.
Subject(s)
Antifungal Agents , COVID-19 , Candidemia , Drug Resistance, Fungal , Fluconazole , Microbial Sensitivity Tests , SARS-CoV-2 , Tertiary Care Centers , Humans , Candidemia/epidemiology , Candidemia/drug therapy , Candidemia/microbiology , Greece/epidemiology , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , COVID-19/epidemiology , Tertiary Care Centers/statistics & numerical data , Fluconazole/pharmacology , Fluconazole/therapeutic use , Candida parapsilosis/drug effects , Candida parapsilosis/isolation & purification , Incidence , Candida auris/drug effects , Candida/drug effects , Candida/isolation & purification , Adult , Male , Female , Middle Aged , Aged , Pandemics , Candidiasis/epidemiology , Candidiasis/drug therapy , Candidiasis/microbiologyABSTRACT
Filamentous cell growth is a vital property of fungal pathogens. The mechanisms of filamentation in the emerging multidrug-resistant fungal pathogen Candida auris are poorly understood. Here, we show that exposure of C. auris to glycerol triggers a rod-like filamentation-competent (RL-FC) phenotype, which forms elongated filamentous cells after a prolonged culture period. Whole-genome sequencing analysis reveals that all RL-FC isolates harbor a mutation in the C2H2 zinc finger transcription factor-encoding gene GFC1 (Gfc1 variants). Deletion of GFC1 leads to an RL-FC phenotype similar to that observed in Gfc1 variants. We further demonstrate that GFC1 mutation causes enhanced fatty acid ß-oxidation metabolism and thereby promotes RL-FC/filamentous growth. This regulation is achieved through a Multiple Carbon source Utilizer (Mcu1)-dependent mechanism. Interestingly, both the evolved RL-FC isolates and the gfc1Δ mutant exhibit an enhanced ability to colonize the skin. Our results reveal that glycerol-mediated GFC1 mutations are beneficial during C. auris skin colonization and infection.
Subject(s)
Candida auris , Candidiasis , Fungal Proteins , Mutation , Candidiasis/microbiology , Fungal Proteins/genetics , Fungal Proteins/metabolism , Candida auris/genetics , Candida auris/metabolism , Mice , Animals , Glycerol/metabolism , Adaptation, Physiological , Transcription Factors/metabolism , Transcription Factors/genetics , Gene Expression Regulation, Fungal , HumansABSTRACT
BACKGROUND: Candida vulturna is an emerging pathogen belonging to the Metshnikowiaceae family together with Candida auris and Candida haemulonii species complex. Some strains of this species were reported to be resistant to several antifungal agents. OBJECTIVES: This study aims to address identification difficulties, evaluate antiungal susceptibilities and explore the molecular mechanisms of azole resistance of Candida vulturna. METHODS: We studied five C. vulturna clinical strains isolated in three Colombian cities. Identification was performed by phenotypical, proteomic and molecular methods. Antifungal susceptibility testing was performed following CLSI protocol. Its ERG11 genes were sequenced and a substitution was encountered in azole resistant isolates. To confirm the role of this substitution in the resistance phenotype, Saccharomyces cerevisiae strains with a chimeric ERG11 gene were created. RESULTS: Discrepancies in identification methods are highlighted. Sequencing confirmed the identification as C. vulturna. Antifungal susceptibility varied among strains, with four strains exhibiting reduced susceptibility to azoles and amphotericin B. ERG11 sequencing showed a point mutation (producing a P135S substitution) that was associated with the azole-resistant phenotype. CONCLUSIONS: This study contributes to the understanding of C. vulturna's identification challenges, its susceptibility patterns, and sheds light on its molecular mechanisms of azole resistance.
Subject(s)
Antifungal Agents , Azoles , Candida , Candidiasis , Microbial Sensitivity Tests , Antifungal Agents/pharmacology , Azoles/pharmacology , Candida/drug effects , Candida/genetics , Candida/classification , Candida/isolation & purification , Candidiasis/microbiology , Humans , Drug Resistance, Multiple, Fungal/genetics , Colombia , Amphotericin B/pharmacology , Drug Resistance, Fungal/genetics , Point Mutation , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/drug effects , Cytochrome P-450 Enzyme System/genetics , Fungal Proteins/genetics , Sequence Analysis, DNA , Saccharomyces cerevisiae ProteinsABSTRACT
Herein, we aimed to investigate the antifungal susceptibility pattern of Candida auris clinical strains in our setting Bahrain Oncology Center-King Hamad University Hospital-Bahrain. C. auris strains isolated from different clinical specimens in the Microbiology Laboratory from October-2021 to November-2022 were evaluated. Species-level identification of fungi was performed by MALDI-TOF (Bruker, Germany). Minimum inhibitory concentration (MIC) was determined either by E-test strips or by MICRONAUT MIC system based on CDC guidelines for C. auris antifungal interpretation. Fluconazole, amphotericin-B, voriconazole, and caspofungin susceptibility data of the clinical strains were analyzed. A total of 40 clinical isolates were included: 25% were blood culture isolates, 65% were urinary, and 10% were soft tissue isolates. Only 29 strains could be tested for amphotericin-B and 32 for voriconazole. Overall resistance pattern was as follows: 100% resistance to fluconazole, 2.5% resistance to caspofungin, and 0% resistance to amphotericin b. Median voriconazole MIC was 0.015 ug/ml (min 0.08, max= 0.064 ug/ml). We had no fluconazole-sensitive strain and only one caspofungin-resistant strain. A single isolate (2.5%), which was associated with candidemia, demonstrated resistance to two antifungal agents: fluconazole and caspofungin. No triple or quadruple drug resistant strain existed.
Subject(s)
Antifungal Agents , Candida auris , Candidiasis , Drug Resistance, Fungal , Hospitals, University , Microbial Sensitivity Tests , Antifungal Agents/pharmacology , Humans , Candidiasis/microbiology , Candida auris/drug effects , Female , Male , Adult , Voriconazole/pharmacology , Middle Aged , Tertiary Care Centers , Tertiary Healthcare , Caspofungin/pharmacology , Candida/drug effects , Candida/isolation & purificationABSTRACT
INTRODUCTION: Drug resistance to echinocandins, first-line drugs used to treat Candida auris infection, is rapidly emerging. However, the accumulation of mutations in genes other than FKS1 (before an isolate develops to resistance via FKS1 mutations), remains poorly understood. Methods: Four clinical cases and 29 isolates associated with the incremental process of echinocandin resistance were collected and analyzed using antifungal drug susceptibility testing and genome sequencing to assess the evolution of echinocandin resistance. FINDINGS: Six echinocandin minimum inhibitory concentration (MIC)-elevated C. auris strains and seven resistant strains were isolated from the urinary system of patients receiving echinocandin treatment. Meanwhile, phylogenetic analyses illustrated that the echinocandin-resistant strains were closely related to other strains in the same patient. Genomic data revealed that the echinocandin-resistant strains had FKS1 mutations. Furthermore, three categories (ECN-S/E/R) of non-synonymous mutant SNP genes (such as RBR3, IFF6, MKC1, MPH1, RAD2, and MYO1) in C. auris appeared to be associated with the three-stage-evolutionary model of echinocandin resistance in C. glabrata: cell wall stress, drug adaptation, and genetic escape (FKS mutation). INTERPRETATION: Echinocandin-resistant C. auris undergoes spatial and temporal phase changes closely related to echinocandin exposure, particularly in the urinary system. These findings suggest that FKS1 mutations mediate an evolutionary accumulation of echinocandin resistance followed by modulation of chromosome remodelling and DNA repair processes that ultimately lead to FKS1 hot spot mutations and the development of drug resistance. This study provides an in-depth exploration of the molecular pathways involved in the evolution of Candida auris echinocandin resistance.
Subject(s)
Antifungal Agents , Candida auris , Candidiasis , Drug Resistance, Fungal , Echinocandins , Fungal Proteins , Microbial Sensitivity Tests , Mutation , Phylogeny , Humans , Echinocandins/pharmacology , Antifungal Agents/pharmacology , Drug Resistance, Fungal/genetics , Candidiasis/microbiology , Candidiasis/drug therapy , Fungal Proteins/genetics , Fungal Proteins/metabolism , Candida auris/genetics , Candida auris/drug effects , Evolution, Molecular , Male , Female , Glucosyltransferases/genetics , Candidiasis, InvasiveABSTRACT
Meyerozyma guilliermondii (Candida guilliermondii) is one of the Candida species associated with invasive candidiasis. With the potential for expressing industrially important enzymes, M. guilliermondii strain SO possessed 99 % proteome similarity with the clinical ATCC 6260 isolate and showed pathogenicity towards zebrafish embryos. Recently, three secreted aspartyl proteinases (SAPs) were computationally identified as potential virulence factors in this strain without in vitro verification of SAP activity. The quantification of Candida SAPs activity in liquid broth were also scarcely reported. Thus, this study aimed to characterize M. guilliermondii strain SO's ability to produce SAPs (MgSAPs) in different conditions (morphology and medium) besides analyzing its growth profile. MgSAPs' capability to cleave bovine serum albumin (BSA) was also determined to propose that MgSAPs as the potential virulence factors compared to the avirulent Saccharomyces cerevisiae. M. guilliermondii strain SO produced more SAPs (higher activity) in yeast nitrogen base-BSA-dextrose broth compared to yeast extract-BSA-dextrose broth despite insignificantly different SAP activity in both planktonic and biofilm cells. FeCl3 supplementation significantly increased the specific protein activity (â¼40 %). The BSA cleavage by MgSAPs at an acidic pH was proven through semi-quantitative SDS-PAGE, sharing similar profile with HIV-1 retropepsin. The presented work highlighted the MgSAPs on fungal cell wall and extracellular milieu during host infection could be corroborated to the quantitative production in different growth modes presented herein besides shedding lights on the potential usage of retropepsin's inhibitors in treating candidiasis. Molecular and expression analyses of MgSAPs and their deletion should be further explored to attribute their respective virulence effects.
Subject(s)
Aspartic Acid Proteases , Biofilms , Candidiasis , Serum Albumin, Bovine , Virulence Factors , Virulence Factors/metabolism , Virulence Factors/genetics , Aspartic Acid Proteases/metabolism , Aspartic Acid Proteases/genetics , Candidiasis/microbiology , Serum Albumin, Bovine/metabolism , Biofilms/growth & development , Animals , Fungal Proteins/metabolism , Fungal Proteins/genetics , Culture Media/chemistry , Candida/pathogenicity , Candida/metabolism , Candida/genetics , Saccharomycetales/metabolism , Saccharomycetales/pathogenicity , Saccharomycetales/genetics , VirulenceABSTRACT
Background: NETs, a unique neutrophil immune mechanism, are vital in defending against microbial invasions. Understanding the mechanisms of co-infection by Candida albicans and Staphylococcus aureus, which often leads to higher mortality and poorer prognosis, is crucial for studying infection progression. Methods: In our study, we established a mouse model of subcutaneous infection to characterize the inflammation induced by co-infection. By purifying and extracting NETs to interact with microorganisms, we delve into the differences in their interactions with various microbial species. Additionally, we investigated the differences in NETs production by neutrophils in response to single or mixed microorganisms through the interaction between neutrophils and these microorganisms. Furthermore, we analyzed the gene expression differences during co-infection using transcriptomics. Results: In vivo, C. albicans infections tend to aggregate, while S. aureus infections are more diffuse. In cases of co-infection, S. aureus adheres to and wraps C. albicans. NETs exhibit strong killing capability against C. albicans but weaker efficacy against S. aureus. When NETs interact with mixed microorganisms, they preferentially target and kill the outer layer of S. aureus. In the early stages, neutrophils primarily rely on phagocytosis to kill S. aureus, but as the bacteria accumulate, they stimulate neutrophils to produce NETs. Interestingly, in the presence of neutrophils, S. aureus promotes the proliferation and hyphal growth of C. albicans. Conclusion: Our research has showed substantial differences in the progression of co-infections compared to single-microbial infections, thereby providing scientific evidence for NETs as potential therapeutic targets in the treatment of co-infections.
Subject(s)
Candida albicans , Candidiasis , Coinfection , Extracellular Traps , Neutrophils , Staphylococcal Infections , Staphylococcus aureus , Candida albicans/immunology , Animals , Extracellular Traps/immunology , Staphylococcus aureus/immunology , Neutrophils/immunology , Mice , Coinfection/immunology , Staphylococcal Infections/immunology , Staphylococcal Infections/microbiology , Candidiasis/immunology , Candidiasis/microbiology , Disease Models, Animal , Phagocytosis/immunology , Female , Mice, Inbred C57BL , Immune EvasionABSTRACT
There is no precise information available on the entire workload of isolating a specific microorganism in a clinical microbiology laboratory, and the costs associated with it have not been specifically estimated. In this descriptive retrospective study conducted at the microbiology department of a general teaching hospital from January 2021 to December 2022, we assessed the workload associated with identifying Candida species in all types of clinical samples and patients. Costs were estimated from data obtained from the hospital's finance department and microbiology laboratory cost records. In 2 years, 1,008,231 samples were processed at our microbiology department, of which 8,775 had one or more Candida spp. isolates (9,683 total isolates). Overall, 5,151 samples with Candida spp. were identified from 2,383 inpatients. We isolated Candida spp. from 515.3 samples/100,000 population/year and from 92 samples/1,000 hospital admissions/year. By sample type, 90.8% were superficial, mainly mucosal. Only 9.1% Candida spp. were isolated from deep, usually sterile, samples, being mostly from ordinarily sterile fluids. Candida albicans was the main species (58.5%) identified, followed by C. parapsilosis complex, C. glabrata, C. tropicalis, and C. krusei. In admitted patients, the incidences of samples with Candida spp. isolates were 302.7 samples/100,000 population/year and 54 samples/1,000 admissions/year. The average cost of isolating and identifying Candida spp. was estimated at 25 per culture-positive sample. To our knowledge, this is the first attempt to gage the workload and costs of Candida spp. isolation at a hospital microbiology department. These data can help assess the burden and significance of Candida isolation at other institutions and also help design measures for streamlining. IMPORTANCE: We believe that this work is of interest because at present, there is no really accurate information available on the total workload involved in isolating a specific microorganism in a clinical microbiology laboratory. The costs related to this have also not been described. We have described the unrestricted workload of Candida spp. in all types of samples for all types of species and patients. We believe that this information would be necessary to collect and share this information as well as to collect it in a standardized way to know the current situation of Candida spp. workload in all clinical microbiology laboratories.
Subject(s)
Candida , Candidiasis , Humans , Candida/isolation & purification , Candida/classification , Retrospective Studies , Candidiasis/microbiology , Male , Female , Middle Aged , Aged , Adult , Workload , Aged, 80 and over , Adolescent , Young Adult , Child , Child, Preschool , InfantABSTRACT
BACKGROUND: Bacterial aggregation has been shown to occur in synovial fluid which are resistant to high concentrations of antibiotics. Yet the propensity of Candida spp. to form aggregates is unknown. OBJECTIVE: To assess the ability of numerous Candida spp. to form synovial fluid aggregates and the clinical ramifications of the aggregates. METHODS: Nine different Candidal prosthetic joint infection clinical isolates were evaluated for their ability to form aggregates at static and dynamic conditions and their resistance to high concentrations of amphotericin. Furthermore, the ability of tissue plasminogen activator (TPA) to disrupt the aggregates and enhance amphotericin activity was assessed. RESULTS: The results show that all species of Candida spp. evaluated formed aggregates in synovial fluid under dynamic conditions that were resistant to amphotericin. Yet no aggregates formed in tryptic soy broth under any conditions or in synovial fluid under static conditions. As well, when TPA was combined with amphotericin there was a statistically significant decrease (p < .005) in the amount of colony forming units per mL for all Candidal species evaluated. Interestingly, for Candida krusei there was no colony forming units observed after exposure to TPA and amphotericin. CONCLUSION: Our findings suggest that Candidal species form synovial fluid aggregates that are resistant to high dose amphotericin similar to those that occur with bacteria. However, the varying ability of the different Candida spp. to form hyphae and pseudohyphae compared to yeast cells may have direct impacts on the hardiness of the aggregates and thereby have clinical ramifications with respect to treatment durations.
Subject(s)
Amphotericin B , Antifungal Agents , Candida , Prosthesis-Related Infections , Synovial Fluid , Synovial Fluid/microbiology , Candida/drug effects , Candida/isolation & purification , Candida/classification , Humans , Prosthesis-Related Infections/microbiology , Prosthesis-Related Infections/drug therapy , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Amphotericin B/pharmacology , Amphotericin B/therapeutic use , Microbial Sensitivity Tests , Candidiasis/microbiology , Candidiasis/drug therapy , Tissue Plasminogen Activator , Drug Resistance, FungalABSTRACT
Candida auris is an emerging, multidrug-resistant fungal pathogen that poses a significant public health threat in healthcare settings. Despite yearly clinical cases rapidly increasing from 77 to 8,131 in the last decade, surveillance data on its distribution and prevalence remain limited. We implemented a novel assay for C. auris detection on a nationwide scale prospectively from September 2023 to March 2024, analyzing a total of 13,842 samples from 190 wastewater treatment plants across 41 U.S. states. Assays were extensively validated through comparison to other known assays and internal controls. Of these 190 wastewater treatment plants, C. auris was detected in the wastewater solids of 65 of them (34.2%) with 1.45% of all samples having detectable levels of C. auris nucleic-acids. Detections varied seasonally, with 2.00% of samples positive in autumn vs 1.01% in winter (P < 0.0001). The frequency of detection in wastewater was significantly associated with states having older populations (P < 0.001), sewersheds containing more hospitals (P < 0.0001), and sewersheds containing more nursing homes (P < 0.001). These associations are in agreement with known C. auris epidemiology. This nationwide study demonstrates the viability of wastewater surveillance for C. auris surveillance and further highlights the value of wastewater surveillance when clinical testing is constrained. IMPORTANCE: This study highlights the viability of wastewater surveillance when dealing with emerging pathogens. By leveraging an existing framework of wastewater surveillance, we reveal the widespread presence of C. auris in the United States. We further demonstrate that these wastewater detections are consistent with demographic factors relevant to C. auris epidemiology like age and number of hospitals or nursing homes. As C. auris and other pathogens continue to emerge, the low-cost and rapid nature of wastewater surveillance will provide public health officials with the information necessary to enact targeted prevention and control strategies.